COBALT advises AbbVie in acquisition of Allergan

The research-based global biopharmaceutical company Abbvie has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement. AbbVie acquired Allergan in a cash and stock transaction for a transaction equity value of approximately USD 63 billion.

With the Allergan acquisition, AbbVie is bringing together over 30 brands, creating a biopharmaceutical company with leadership positions in such key therapeutic areas as immunology, oncology, neuroscience, eye care, virology, women’s health, gastroenterology and aesthetics.

During the takeover of Allergan, merger of local businesses and structure simplification COBALT acted as legal advisor for AbbVie on Latvian corporate law, pharmaceutical regulatory, data protection, tax law and employment issues. The team was led by Partner and Head of the IP, IT and Regulatory practice Indriķis Liepa with the assistance of Partner Sandija Novicka, Senior Associate Ivo Maskalāns and Associate Marija Berdova.